We at Qureator, pioneers in animal-POC-free IND submission, are thrilled to announce our first-ever anti–PD-1/L1 combination and PD-1/VEGF bispecific campaigns. We are offering our pharmaceutical and biotech partners a special launch offer to experience our revolutionary vTIME (vascularized Tumor Immune Microenvironment) platform.
This campaign follows the landmark October 6, 2025 FDA approval of SillaJen’s IND, which was based solely on Qureator’s human-relevant efficacy data — a first for the industry and a testament to our platform’s predictive power.
Our vTIME platform, fully compliant with the FDA Modernization Act 2.0, replaces obsolete animal proof-of-concept models. By combining high-throughput CURIOCHIPS (Organ-on-a-Chip) technology with AI-powered QURICORE prediction, we deliver a complete, IND-ready efficacy package in just four weeks. These campaigns enable partners to quantify PD-1/L1 synergy, T-cell activation, tumor killing, and VEGF-driven vascular modulation in a patient-derived tumor microenvironment.
Spots for this special launch offer are limited. Please contact us for more information.